CAN A COMMERCIAL DIAGNOSTIC ULTRASOUND DEVICE ACCELERATE THROMBOLYSIS?—AN IN VITRO STROKE MODEL

Stefan Pfaffenberger(Medical University of Vienna), Michael Gottsauner‐Wolf(Medical University of Vienna), Christian Kollmann(University of Vienna), Stefan Kastl(Medical University of Vienna), Gerald Maurer(European Society of Radiology), Kurt Huber(Sigmund Freud Privatuniversität Wien), Branka Devcic-Kuhar(University of Vienna), Thomas W. Weiss(University of Vienna), Walter S. Speidl(University of Applied Sciences St Pölten), Christoph Kaun(University of Vienna), Johann Wojta(Medical University of Vienna)
Cardiovascular Pathology
April 29, 2004
10.1016/j.carpath.2004.03.530
Cited by 1

Related Papers

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
|The Lancet|2018|793
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755